EA201171333A1 - Кристаллические сольваты и комплексы производных (1s)-1,5-ангидро-1-с-(3-((фенил)метил)фенил)-d-глюцитола с аминокислотами в качестве ингибиторов sglt2 для лечения диабета - Google Patents

Кристаллические сольваты и комплексы производных (1s)-1,5-ангидро-1-с-(3-((фенил)метил)фенил)-d-глюцитола с аминокислотами в качестве ингибиторов sglt2 для лечения диабета

Info

Publication number
EA201171333A1
EA201171333A1 EA201171333A EA201171333A EA201171333A1 EA 201171333 A1 EA201171333 A1 EA 201171333A1 EA 201171333 A EA201171333 A EA 201171333A EA 201171333 A EA201171333 A EA 201171333A EA 201171333 A1 EA201171333 A1 EA 201171333A1
Authority
EA
Eurasian Patent Office
Prior art keywords
phenyl
glycitol
anhydro
complexes
derivatives
Prior art date
Application number
EA201171333A
Other languages
English (en)
Other versions
EA020428B1 (ru
Inventor
Джек З. Гугутас
Хильдегард Лобингер
Шривидья Рамакришнан
Прашант П. Дешпанде
Джеффри Т. Бйн
Чиаджень Лай
Ченьчи Ванг
Петер Рибель
Джон Энтони Гроссо
Александра А. Нёршль
Джанак Сингх
Джон Д. Димарко
Original Assignee
Бристол-Маерс Сквибб Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38581970&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201171333(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Бристол-Маерс Сквибб Компани filed Critical Бристол-Маерс Сквибб Компани
Publication of EA201171333A1 publication Critical patent/EA201171333A1/ru
Publication of EA020428B1 publication Critical patent/EA020428B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/207—Cyclohexane rings not substituted by nitrogen atoms, e.g. kasugamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/04—Carbocyclic radicals

Abstract

Настоящее изобретение относится к кристаллическим формам соединения формулы I, в частности к фармацевтическим композициям, содержащим структуру соединения I, к способам их получения, к промежуточным соединениям, используемым для их получения, и к способам лечения заболеваний, таких как диабет, с использованием таких структур.
EA201171333A 2006-06-28 2007-06-21 Кристаллические сольваты производных (1s)-1,5-ангидро-1-с-(3-((фенил)метил)фенил)-d-глюцитола в качестве ингибиторов sglt2 для лечения диабета EA020428B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81711806P 2006-06-28 2006-06-28
US11/765,481 US7919598B2 (en) 2006-06-28 2007-06-20 Crystal structures of SGLT2 inhibitors and processes for preparing same

Publications (2)

Publication Number Publication Date
EA201171333A1 true EA201171333A1 (ru) 2012-04-30
EA020428B1 EA020428B1 (ru) 2014-11-28

Family

ID=38581970

Family Applications (4)

Application Number Title Priority Date Filing Date
EA201791254A EA035999B1 (ru) 2006-06-28 2007-06-21 Кристаллические сольваты и комплексы производных (1s)-1,5-ангидро-1-c-(3-((фенил)метил)фенил)-d-глюцитола с аминокислотами в качестве ингибиторов sglt2 для лечения диабета
EA200900066A EA018229B1 (ru) 2006-06-28 2007-06-21 Кристаллические сольваты и комплексы производных (1s)-1,5-ангидро-1-c-(3-((фенил)метил)фенил)-d-глюцитола с аминокислотами в качестве ингибиторов sglt2 для лечения диабета
EA201171333A EA020428B1 (ru) 2006-06-28 2007-06-21 Кристаллические сольваты производных (1s)-1,5-ангидро-1-с-(3-((фенил)метил)фенил)-d-глюцитола в качестве ингибиторов sglt2 для лечения диабета
EA201490902A EA028259B1 (ru) 2006-06-28 2007-06-21 Кристаллический сольват производного (1s)-1,5-ангидро-1-c-(3-((фенил)метил)фенил)-d-глюцитола с аминокислотой и способ его получения

Family Applications Before (2)

Application Number Title Priority Date Filing Date
EA201791254A EA035999B1 (ru) 2006-06-28 2007-06-21 Кристаллические сольваты и комплексы производных (1s)-1,5-ангидро-1-c-(3-((фенил)метил)фенил)-d-глюцитола с аминокислотами в качестве ингибиторов sglt2 для лечения диабета
EA200900066A EA018229B1 (ru) 2006-06-28 2007-06-21 Кристаллические сольваты и комплексы производных (1s)-1,5-ангидро-1-c-(3-((фенил)метил)фенил)-d-глюцитола с аминокислотами в качестве ингибиторов sglt2 для лечения диабета

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA201490902A EA028259B1 (ru) 2006-06-28 2007-06-21 Кристаллический сольват производного (1s)-1,5-ангидро-1-c-(3-((фенил)метил)фенил)-d-глюцитола с аминокислотой и способ его получения

Country Status (33)

Country Link
US (3) US7919598B2 (ru)
EP (4) EP2069374B2 (ru)
JP (6) JP5313889B2 (ru)
KR (1) KR101493102B1 (ru)
CN (2) CN103145773B (ru)
AR (1) AR061730A1 (ru)
AU (1) AU2007265246B2 (ru)
BR (3) BRPI0713544B8 (ru)
CA (3) CA2924318C (ru)
CL (1) CL2007001915A1 (ru)
CO (1) CO6160299A2 (ru)
CY (1) CY1115738T1 (ru)
DK (1) DK2069374T4 (ru)
EA (4) EA035999B1 (ru)
ES (3) ES2769130T3 (ru)
HK (1) HK1127359A1 (ru)
HR (1) HRP20141007T4 (ru)
IL (5) IL195882A (ru)
MX (3) MX367155B (ru)
MY (2) MY173930A (ru)
NO (2) NO346828B1 (ru)
NZ (4) NZ574346A (ru)
PE (2) PE20120776A1 (ru)
PH (1) PH12012500168A1 (ru)
PL (1) PL2069374T5 (ru)
PT (1) PT2069374E (ru)
RS (1) RS53638B2 (ru)
SG (2) SG10201402181SA (ru)
SI (1) SI2069374T2 (ru)
TW (4) TWI519528B (ru)
UA (1) UA96765C2 (ru)
WO (1) WO2008002824A1 (ru)
ZA (1) ZA200810475B (ru)

Families Citing this family (151)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006020049A2 (en) 2004-07-15 2006-02-23 Amr Technology, Inc. Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
TW200726755A (en) * 2005-07-07 2007-07-16 Astellas Pharma Inc A crystalline choline salt of an azulene derivative
TWI370818B (en) * 2006-04-05 2012-08-21 Astellas Pharma Inc Cocrystal of c-glycoside derivative and l-proline
US7919598B2 (en) * 2006-06-28 2011-04-05 Bristol-Myers Squibb Company Crystal structures of SGLT2 inhibitors and processes for preparing same
WO2008075736A1 (ja) * 2006-12-21 2008-06-26 Astellas Pharma Inc. Ｃ－グリコシド誘導体の製造方法及びその合成中間体
TW200904454A (en) 2007-03-22 2009-02-01 Bristol Myers Squibb Co Methods for treating obesity employing an SGLT2 inhibitor and compositions thereof
PE20090185A1 (es) 2007-03-22 2009-02-28 Bristol Myers Squibb Co Formulaciones farmaceuticas que contienen un inhibidor sglt2
EP2147008A2 (en) * 2007-05-18 2010-01-27 Bristol-Myers Squibb Company Crystal structures of sglt2 inhibitors and processes for preparing same
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
UA101004C2 (en) 2007-12-13 2013-02-25 Теракос, Инк. Derivatives of benzylphenylcyclohexane and use thereof
CN104387354A (zh) * 2007-12-27 2015-03-04 阿斯利康公司 Sglt2 抑制剂的晶体结构及其制备方法
CN101468976B (zh) * 2007-12-27 2013-11-20 百时美施贵宝公司 Sglt2抑制剂的晶体结构及其制备方法
CN101969944B (zh) * 2008-01-31 2013-04-10 安斯泰来制药有限公司 脂肪性肝病的治疗用医药组合物
WO2009117367A1 (en) * 2008-03-18 2009-09-24 Bristol-Myers Squibb Company Method for treating cancers having high glucose requirements employing an sglt2 inhibitor and compositions thereof
JP5820269B2 (ja) * 2008-05-22 2015-11-24 アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ Ｓｇｌｔ２阻害剤を使用する高尿酸血症の治療方法およびｓｇｌｔ２阻害剤を含有する組成物
WO2009143021A1 (en) * 2008-05-22 2009-11-26 Bristol-Myers Squibb Company Method for treating and preventing kidney stones employing an sglt2 inhibitor and composition containing same
US8518895B2 (en) * 2008-05-22 2013-08-27 Bristol-Myers Squibb Company Method for treating hyponatremia employing an SGLT2 inhibitor and composition containing same
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
CA2730734C (en) 2008-07-15 2017-04-25 Theracos, Inc. Deuterated 2,3,4-trihydroxy-tetrahydropyranyl-benzylbenzene compounds having sodium glucose cotransporter inhibitory activity
KR101654231B1 (ko) 2008-08-22 2016-09-05 테라코스 서브, 엘엘씨 Ｓｇｌｔ２ 억제제의 제조방법
AU2014201286B2 (en) * 2008-08-22 2015-07-02 Theracosbio, Llc Processes for the preparation of SGLT2 inhibitors
AU2009286380B2 (en) 2008-08-28 2011-09-15 Pfizer Inc. Dioxa-bicyclo[3.2.1.]octane-2,3,4-triol derivatives
LT2395983T (lt) 2009-02-13 2020-07-10 Boehringer Ingelheim International Gmbh Farmacinė kompozicija, apimanti sglt2 inhibitorių, dpp-iv inhibitorių ir, pasirinktinai, papildomą priešdiabetinį agentą, bei jos panaudojimas
JP5739415B2 (ja) 2009-05-12 2015-06-24 ブリストル−マイヤーズ スクウィブ カンパニー （Ｓ）−７−（［１，２，４］トリアゾロ［１，５−ａ］ピリジン−６−イル）−４−（３，４−ジクロロフェニル）−１，２，３，４−テトラヒドロイソキノリンの結晶形態およびその使用
KR20120034644A (ko) 2009-05-12 2012-04-12 알바니 몰레큘라 리써치, 인크. 아릴, 헤테로아릴, 및 헤테로사이클 치환된 테트라하이드로이소퀴놀린 및 이의 용도
DK2429296T3 (en) * 2009-05-12 2018-03-12 Albany Molecular Res Inc 7 - ([1,2,4,] TRIAZOLO [1,5, -A] PYRIDIN-6-YL) -4- (3,4-DICHLORPHENYL) -1,2,3,4- TETRAHYDROISOQUINOLINE AND USE thereof
US20110009347A1 (en) 2009-07-08 2011-01-13 Yin Liang Combination therapy for the treatment of diabetes
AU2010310956B2 (en) 2009-11-02 2014-05-08 Pfizer Inc. Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
RU2712757C3 (ru) 2009-11-13 2021-06-09 Астразенека Аб Композиция двухслойной таблетки
EP2498759B1 (en) 2009-11-13 2018-08-01 AstraZeneca AB Immediate release tablet formulations
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2011120923A1 (en) 2010-03-30 2011-10-06 Boehringer Ingelheim International Gmbh Pharmaceutical composition comprising an sglt2 inhibitor and a ppar- gamma agonist and uses thereof
CN102883726A (zh) 2010-05-11 2013-01-16 詹森药业有限公司 包含1-(β-D-吡喃葡萄糖基)-2-噻吩基-甲基苯衍生物作为SGLT抑制剂的药物制剂
WO2011153712A1 (en) 2010-06-12 2011-12-15 Theracos, Inc. Crystalline form of benzylbenzene sglt2 inhibitor
WO2011157827A1 (de) 2010-06-18 2011-12-22 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
WO2012025857A1 (en) 2010-08-23 2012-03-01 Hetero Research Foundation Cycloalkyl methoxybenzyl phenyl pyran derivatives as sodium dependent glucose co transporter (sglt2) inhibitors
EP2611442B1 (en) 2010-09-03 2018-07-04 Bristol-Myers Squibb Company Drug formulations using water soluble antioxidants
WO2012041898A1 (en) 2010-09-29 2012-04-05 Celon Pharma Sp. Z O.O. Combination of sglt2 inhibitor and a sugar compound for the treatment of diabetes
US20120283169A1 (en) 2010-11-08 2012-11-08 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
RU2607480C2 (ru) 2011-02-01 2017-01-10 Бристол-Майерс Сквибб Компани Фармацевтические композиции, содержащие аминосоединение
US20130035281A1 (en) 2011-02-09 2013-02-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
AU2012241897C1 (en) 2011-04-13 2017-05-11 Janssen Pharmaceutica Nv Process for the preparation of compounds useful as inhibitors of SGLT2
TWI542596B (zh) * 2011-05-09 2016-07-21 健生藥品公司 （２ｓ,３ｒ,４ｒ,５ｓ,６ｒ）－２－（３－（（５－（４－氟苯基）噻吩－２－基）甲基）－４－甲基苯基）－６－（羥甲基）四氫－２ｈ－哌喃－３,４,５－三醇之ｌ－脯胺酸及檸檬酸共晶體
MX2013014135A (es) 2011-06-03 2014-01-23 Boehringer Ingelheim Int Inhibidores de sglt2 para tratar trastornos metabolicos en pacientes tratados con agentes neurolepticos.
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
CN103889429B (zh) * 2011-10-31 2016-10-19 台湾神隆股份有限公司 Sglt2抑制剂的结晶和非结晶形式
EP2597090A1 (en) * 2011-11-28 2013-05-29 Sandoz AG Crystalline dapagliflozin hydrate
TW201335176A (zh) 2011-12-15 2013-09-01 Nat Health Research Institutes 新穎醣苷化合物
US9193751B2 (en) 2012-04-10 2015-11-24 Theracos, Inc. Process for the preparation of benzylbenzene SGLT2 inhibitors
US9145434B2 (en) 2012-07-26 2015-09-29 Boehringer Ingelheim International Gmbh Crystalline complex of 1-cyano-2-(4-cyclopropyl-benzyl)-4-(ss-d-glucopyranos-1-yl)-benzene, methods for its preparation and the use thereof for preparing medicaments
CN103910769B (zh) * 2012-12-31 2018-10-02 上海璎黎药业有限公司 葡萄糖衍生物和脯氨酸的复合物、晶体、制备方法及应用
CN103910719B (zh) * 2012-12-31 2018-05-01 上海璎黎药业有限公司 葡萄糖衍生物与苯丙氨酸复合物、晶体、制备方法及应用
US9573959B2 (en) 2013-03-14 2017-02-21 Msd International Gmbh Methods for preparing SGLT2 inhibitors
PL2981269T3 (pl) 2013-04-04 2024-02-05 Boehringer Ingelheim Vetmedica Gmbh Leczenie zaburzeń metabolicznych u zwierząt koniowatych
WO2014178040A1 (en) 2013-04-29 2014-11-06 Mapi Pharma Ltd. Co-crystals of dapagliflozin
US20160214953A1 (en) 2013-09-23 2016-07-28 Sun Pharmaceutical Industries Limited Process for the preparation of dapagliflozin
EP3049397A1 (en) 2013-09-27 2016-08-03 Sun Pharmaceutical Industries Ltd Process for the purification of dapagliflozin
WO2015051484A1 (en) 2013-10-12 2015-04-16 Theracos, Inc. Preparation of hydroxy-benzylbenzene derivatives
WO2015063726A1 (en) 2013-10-31 2015-05-07 Ranbaxy Laboratories Limited Process for the preparation of 4-bromo-1-chloro-2-(4-ethoxybenzyl)benzene
MX2016007856A (es) 2013-12-17 2016-10-07 Boehringer Ingelheim Vetmedica Gmbh Tratamiento de trastornos metabolicos en animales felinos.
KR102414283B1 (ko) 2014-01-23 2022-06-29 베링거잉겔하임베트메디카게엠베하 개과 동물에서 대사 장애의 치료
CN104829572B (zh) * 2014-02-10 2019-01-04 江苏豪森药业集团有限公司 达格列净新晶型及其制备方法
US20170056365A1 (en) 2014-02-28 2017-03-02 Sun Pharmaceutical Industries Limited Dapagliflozin compositions
US20170029398A1 (en) * 2014-03-06 2017-02-02 Srinivasan Thirumalai Rajan Process for the preparation of (1s)-1,5-anhydro-1-c-{4-chloro-3-4[(4-ethoxyphenyl)methyl]phenyl]-glucitol and its solvate thereof
EP3125882B1 (en) 2014-04-01 2020-05-13 Boehringer Ingelheim Vetmedica GmbH Treatment of metabolic disorders in equine animals
CN106459120A (zh) 2014-05-19 2017-02-22 辉瑞大药厂 作为asgpr靶向剂的被取代的‑6,8‑二氧杂双环[3.2.1]辛烷‑2,3‑二醇化合物
CN104031098A (zh) * 2014-06-21 2014-09-10 李友香 降糖药物
CN104017031A (zh) * 2014-06-21 2014-09-03 李友香 降血糖药物和组合物
WO2015198227A1 (en) * 2014-06-23 2015-12-30 Sun Pharmaceutical Industries Limited Co-crystal of dapagliflozin with citric acid
KR20160013770A (ko) * 2014-07-28 2016-02-05 한미정밀화학주식회사 다파글리프로진의 신규 결정질 복합체 및 이의 제조방법
CN106714840A (zh) 2014-09-25 2017-05-24 阿斯利康(瑞典)有限公司 用于治疗肝病的ω‑3脂肪酸和SGLT‑2抑制剂的组合
WO2016046150A1 (en) 2014-09-25 2016-03-31 Boehringer Ingelheim Vetmedica Gmbh Combination treatment of sglt2 inhibitors and dopamine agonists for preventing metabolic disorders in equine animals
CN104496952B (zh) * 2014-11-28 2017-04-19 深圳翰宇药业股份有限公司 一种达格列净的合成方法
US20170342100A1 (en) * 2014-12-03 2017-11-30 Sun Pharmaceutical Industries Limited Processes for the preparation of ertugliflozin
CZ2015110A3 (cs) * 2015-02-18 2016-08-31 Zentiva, K.S. Pevné formy empagliflozinu
WO2016147197A1 (en) * 2015-03-17 2016-09-22 Harman Finochem Limited A novel process for preparing (2s,3r,4r,5s,6r)-2-[4-chloro-3-(4-ethoxybenzyl)pheny 1] -6-(hy droxy methyl)tetrahydro-2h-py ran-3,4,5-triol and its amorphous form
WO2016155578A1 (zh) * 2015-03-27 2016-10-06 苏州晶云药物科技有限公司 达格列净的新晶型及其制备方法
WO2016161995A1 (en) 2015-04-08 2016-10-13 Zentiva, K.S. Solid forms of amorphous dapagliflozin
CN106146446B (zh) * 2015-04-17 2019-11-08 杭州领业医药科技有限公司 达格列净半水合物及其晶型、其制备方法及药物组合物
US10556877B2 (en) 2015-05-05 2020-02-11 Glenmark Life Sciences Limited Process for preparation of dapagliflozin
JP6896651B2 (ja) 2015-06-17 2021-06-30 オオツカアメリカファーマシューティカル、インコーポレイテッド 結晶性化合物
WO2017042683A1 (en) * 2015-09-07 2017-03-16 Dr. Reddy's Laboratories Limited Isolated intermediate of dapagliflozin, process for the preparation of isolated intermediate of dapagliflozin, process for the preparation of dapagliflozin
ES2896101T3 (es) 2015-09-15 2022-02-23 Laurus Labs Ltd Cocristales de inhibidores de SGLT2, procedimiento para su preparación y composiciones farmacéuticas de los mismos
WO2017060925A1 (en) * 2015-10-09 2017-04-13 Harman Finochem Limited Novel pipecolic acid co-crystals of dapagliflozin and process for the preparation thereof
US9845303B2 (en) 2015-10-19 2017-12-19 Cadila Healthcare Limited Process for the preparation of dapagliflozin
EP3371199A4 (en) * 2015-11-27 2019-06-12 Sunshine Lake Pharma Co., Ltd. COMPLEX OF A GLUCOPYRANOSYL DERIVATIVE AND METHOD OF PREPARATION AND USE THEREOF
WO2017099496A1 (ko) * 2015-12-11 2017-06-15 동아에스티 주식회사 다파글리플로진의 신규 용매화물 및 이의 제조방법
WO2017118945A1 (en) 2016-01-08 2017-07-13 Lupin Limited Premix of dapagliflozin and process for the preparation thereof
CN105503802A (zh) * 2016-01-15 2016-04-20 中山大学 一种达格列净-柠檬酸共晶的制备方法
WO2017155841A1 (en) 2016-03-11 2017-09-14 Merck Sharp & Dohme Corp. Methods of treating or reducing the risk of cardiovascular events and related diseases using sglt-2 inhibitors
EP3435987A1 (en) 2016-03-31 2019-02-06 Lupin Limited Pharmaceutical composition of dapagliflozin
US10759772B2 (en) * 2016-05-02 2020-09-01 Aurobindo Pharma Ltd Process for the preparation of DL-proline co-crystal of Dapagliflozin
EP3466939B1 (en) * 2016-05-24 2021-02-24 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. New dapagliflozin crystal form and preparation method and use thereof
WO2017203457A1 (en) * 2016-05-26 2017-11-30 Dr. Reddy's Laboratories Limited Solid state forms of empagliflozin
WO2017203229A1 (en) 2016-05-27 2017-11-30 Cipla Limited Dapagliflozin premixes
CN109476624B (zh) * 2016-05-28 2021-07-09 吉林惠升生物制药有限公司 钠-葡萄糖协同转运蛋白2抑制剂的晶型
CN107445932A (zh) * 2016-05-30 2017-12-08 上海医药工业研究院 达格列净共晶物的制备工艺
WO2017221211A1 (en) * 2016-06-24 2017-12-28 Biocon Limited Process for the preparation of dapagliflozin and its solvate thereof
CN107641139A (zh) 2016-07-22 2018-01-30 江苏豪森药业集团有限公司 达格列净中间体的晶型及其制备方法
EA201990951A1 (ru) 2016-10-19 2019-11-29 Комбинации, содержащие ssao/vap-1 ингибитор и sglt2-ингибитор, и их применение
KR20180058510A (ko) * 2016-11-24 2018-06-01 한미약품 주식회사 다파글리플로진 l-프롤린을 포함하는 약제학적 제제
WO2018124497A1 (ko) 2016-12-30 2018-07-05 한미약품 주식회사 다파글리플로진 l-프롤린과 항당뇨병제를 포함하는 약제학적 복합 제제
KR20180078762A (ko) * 2016-12-30 2018-07-10 한미약품 주식회사 다파글리플로진 l-프롤린을 포함하는 당뇨병 질환의 예방 또는 치료용 약제학적 조성물
WO2018167589A1 (en) 2017-03-16 2018-09-20 Inventia Healthcare Private Limited Pharmaceutical composition comprising dapagliflozin
AR112015A1 (es) 2017-06-09 2019-09-11 Novo Nordisk As Composiciones sólidas para administración oral
CN107488156B (zh) * 2017-09-04 2020-05-26 上海现代制药股份有限公司 一种无定型葡萄糖醇的合成方法
WO2019066359A2 (ko) * 2017-09-29 2019-04-04 한미약품 주식회사 다파글리플로진 l-프롤린과 메트포르민을 포함하는 약제학적 복합제제
KR102369679B1 (ko) * 2017-09-29 2022-03-04 한미약품 주식회사 다파글리플로진 l-프롤린과 메트포르민을 포함하는 약제학적 복합제제
CN108516966A (zh) * 2017-10-19 2018-09-11 浙江海正药业股份有限公司 达格列净的晶型及其制备方法和用途
KR20190115948A (ko) 2018-04-04 2019-10-14 한미약품 주식회사 다파글리플로진 l-프롤린을 포함하는 당뇨병 질환의 예방 또는 치료용 약제학적 조성물
JP2021520394A (ja) 2018-04-17 2021-08-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 医薬組成物、処置方法及びその使用
KR102204439B1 (ko) 2018-05-14 2021-01-18 에이치케이이노엔 주식회사 Sglt-2 억제제 및 dpp-iv 억제제를 포함하는 약제학적 조성물
PE20210644A1 (es) 2018-07-19 2021-03-23 Astrazeneca Ab METODOS DE TRATAMIENTO DE HFpEF EMPLEANDO DAPAGLIFLOZINA Y COMPOSICIONES QUE COMPRENDEN LA MISMA
WO2020039394A1 (en) 2018-08-24 2020-02-27 Novartis Ag New drug combinations
CA3113037A1 (en) * 2018-09-26 2020-04-02 Lexicon Pharmaceuticals, Inc. Crystalline forms of n-(1-((2-(dimethylamino)ethyl)amino)-2-methyl-1-oopropan-2-yl)-4-(4-(2-methyl-5-(2s,3r,4r,5s,6r)-3,4,5-trihydroxy-6-(methylthio)tetrahydro-2h-pyran-2-yl)benzyl)phenl)butanamide and methods of their synthesis
EP3860601A1 (en) 2018-10-01 2021-08-11 Astrazeneca AB Compositions for reducing serum uric acid
CN109705075B (zh) * 2018-12-13 2022-12-23 苏中药业集团股份有限公司 一种达格列净的纯化方法
CN109705076B (zh) * 2019-01-21 2023-03-24 苏中药业集团股份有限公司 一种达格列净晶型、制备方法及其用途
CN111559997A (zh) * 2019-02-13 2020-08-21 罗欣药业(上海)有限公司 一种达格列净新晶型及其制备方法
CN111689936A (zh) * 2019-03-15 2020-09-22 罗欣药业(上海)有限公司 达格列净新晶型及其制备方法
US20220395559A1 (en) 2019-11-07 2022-12-15 Novo Nordisk A/S Solid compositions comprising a glp-1 agonist, an sglt2 inhibitor and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid
MX2019014226A (es) * 2019-11-27 2022-09-23 Alparis Sa De Cv Nuevas fases sólidas de dapagliflozina.
UY38969A (es) 2019-11-28 2021-05-31 Boehringer Ingelheim Vetmedica Gmbh Uso de inhibidores de sglt-2 en el secado de mamíferos no humanos
MX2022007945A (es) * 2019-12-24 2022-10-03 Hanmi Pharm Ind Co Ltd Formulacion compleja que comprende sitagliptina y dapagliflozina, y metodo de preparacion de la misma.
KR20220143732A (ko) 2020-02-17 2022-10-25 베링거잉겔하임베트메디카게엠베하 고양이과에서 심장 질환을 예방 및/또는 치료하기 위한 sglt-2 억제제의 사용
CA3169665A1 (en) 2020-02-21 2021-08-26 Zaklady Farmaceutyczne Polpharma S.A. Pharmaceutical composition comprising dapagliflozin
EP4114365A1 (en) 2020-03-05 2023-01-11 KRKA, d.d., Novo mesto Pharmaceutical composition comprising sglt2 inhibitor
JP2023523596A (ja) 2020-04-22 2023-06-06 バイエル アクチェンゲゼルシャフト 心血管疾患および／または腎疾患を治療および／または予防するためのフィネレノンとｓｇｌｔ２阻害剤の組み合わせ
US20230165856A1 (en) 2020-04-29 2023-06-01 Astrazeneca Ab Dapagliflozin and ambrisentan for the prevention and treatment of covid-19
KR20220007446A (ko) * 2020-07-10 2022-01-18 한미약품 주식회사 시타글립틴 및 다파글리플로진을 포함하는 복합제제 및 그 제조방법
WO2022022865A1 (en) 2020-07-27 2022-02-03 Astrazeneca Ab Methods of treating chronic kidney disease with dapagliflozin
WO2022067724A1 (zh) 2020-09-30 2022-04-07 北京睿创康泰医药研究院有限公司 一种sglt-2抑制剂·肌氨酸共晶体及其制备方法和应用
AU2022319909A1 (en) 2021-07-28 2024-02-22 Boehringer Ingelheim Vetmedica Gmbh Use of sglt-2 inhibitors for the prevention and/or treatment of cardiac diseases in non-human mammals excluding felines, in particular canines
WO2023006747A1 (en) 2021-07-28 2023-02-02 Boehringer Ingelheim Vetmedica Gmbh Use of sglt-2 inhibitors for the prevention and/or treatment of renal diseases in non-human mammals
WO2023006745A1 (en) 2021-07-28 2023-02-02 Boehringer Ingelheim Vetmedica Gmbh Use of sglt-2 inhibitors for the prevention and/or treatment of hypertension in non-human mammals
CN114394993B (zh) * 2021-11-11 2023-11-10 苏州正济药业有限公司 一种达格列净中间体的制备方法
CN114213399A (zh) * 2021-12-20 2022-03-22 上海启讯医药科技有限公司 一种卡格列净丙酮水合物及其制备方法和用途
WO2023129595A1 (en) 2021-12-30 2023-07-06 Newamsterdam Pharma B.V. Obicetrapib and sglt2 inhibitor combination
WO2023144722A1 (en) 2022-01-26 2023-08-03 Astrazeneca Ab Dapagliflozin for use in the treatment of prediabetes or reducing the risk of developing type 2 diabetes
WO2023169456A1 (en) 2022-03-09 2023-09-14 Gasherbrum Bio , Inc. Heterocyclic glp-1 agonists
WO2023179542A1 (en) 2022-03-21 2023-09-28 Gasherbrum Bio , Inc. 5,8-dihydro-1,7-naphthyridine derivatives as glp-1 agonists for the treatment of diabetes
WO2023198140A1 (en) 2022-04-14 2023-10-19 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
US20230381101A1 (en) 2022-05-25 2023-11-30 Boehringer Ingelheim Vetmedica Gmbh Aqueous pharmaceutical compositions comprising sglt-2 inhibitors
US20240058331A1 (en) 2022-08-12 2024-02-22 Astrazeneca Ab Combination therapies for treatment of cirrhosis with portal hypertension
WO2024047574A1 (en) 2022-09-01 2024-03-07 Astrazeneca Ab Combination of sglt2 inhibitors and mineralcorticoid receptor modulators for use in treatment of cardiorenal diseases
WO2024062310A1 (en) * 2022-09-22 2024-03-28 Savoi Guilherme Co-crystals derived from empagliflozin and dapagliflozin with l-proline

Family Cites Families (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3674836A (en) 1968-05-21 1972-07-04 Parke Davis & Co 2,2-dimethyl-{11 -aryloxy-alkanoic acids and salts and esters thereof
US4027009A (en) 1973-06-11 1977-05-31 Merck & Co., Inc. Compositions and methods for depressing blood serum cholesterol
JPS5612114B2 (ru) 1974-06-07 1981-03-18
US4231938A (en) 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
MX7065E (es) 1980-06-06 1987-04-10 Sankyo Co Un procedimiento microbiologico para preparar derivados de ml-236b
US4450171A (en) 1980-08-05 1984-05-22 Merck & Co., Inc. Antihypercholesterolemic compounds
US4448784A (en) 1982-04-12 1984-05-15 Hoechst-Roussel Pharmaceuticals, Inc. 1-(Aminoalkylphenyl and aminoalkylbenzyl)-indoles and indolines and analgesic method of use thereof
US5354772A (en) 1982-11-22 1994-10-11 Sandoz Pharm. Corp. Indole analogs of mevalonolactone and derivatives thereof
US4499289A (en) 1982-12-03 1985-02-12 G. D. Searle & Co. Octahydronapthalenes
CA1327360C (en) 1983-11-14 1994-03-01 William F. Hoffman Oxo-analogs of mevinolin-like antihypercholesterolemic agents
US4613610A (en) 1984-06-22 1986-09-23 Sandoz Pharmaceuticals Corp. Cholesterol biosynthesis inhibiting pyrazole analogs of mevalonolactone and its derivatives
US4686237A (en) 1984-07-24 1987-08-11 Sandoz Pharmaceuticals Corp. Erythro-(E)-7-[3'-C1-3 alkyl-1'-(3",5"-dimethylphenyl)naphth-2'-yl]-3,5-dihydroxyhept-6-enoic acids and derivatives thereof
US4647576A (en) 1984-09-24 1987-03-03 Warner-Lambert Company Trans-6-[2-(substitutedpyrrol-1-yl)alkyl]-pyran-2-one inhibitors of cholesterol synthesis
JPS62501009A (ja) 1984-12-04 1987-04-23 サンド・アクチエンゲゼルシヤフト メバロノラクトンのインデン同族体及びその誘導体
US4668794A (en) 1985-05-22 1987-05-26 Sandoz Pharm. Corp. Intermediate imidazole acrolein analogs
AU598775B2 (en) 1985-10-25 1990-07-05 Sandoz Ag Heterocyclic analogs of mevalonolactone
FR2596393B1 (fr) 1986-04-01 1988-06-03 Sanofi Sa Derives de l'acide hydroxy-3 dihydroxyoxophosphorio-4 butanoique, leur procede de preparation, leur application comme medicament et les compositions les renfermant
US5614492A (en) 1986-05-05 1997-03-25 The General Hospital Corporation Insulinotropic hormone GLP-1 (7-36) and uses thereof
US4681893A (en) 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
GB2205837B (en) 1987-05-22 1991-11-20 Squibb & Sons Inc Phosphorus-containing hmg-coa reductase inhibitors
US4759923A (en) 1987-06-25 1988-07-26 Hercules Incorporated Process for lowering serum cholesterol using poly(diallylmethylamine) derivatives
JP2569746B2 (ja) 1987-08-20 1997-01-08 日産化学工業株式会社 キノリン系メバロノラクトン類
US4924024A (en) 1988-01-11 1990-05-08 E. R. Squibb & Sons, Inc. Phosphorus-containing squalene synthetase inhibitors, new intermediates and method
US4871721A (en) 1988-01-11 1989-10-03 E. R. Squibb & Sons, Inc. Phosphorus-containing squalene synthetase inhibitors
NO177005C (no) 1988-01-20 1995-07-05 Bayer Ag Analogifremgangsmåte for fremstilling av substituerte pyridiner, samt mellomprodukter til bruk ved fremstillingen
US5506219A (en) 1988-08-29 1996-04-09 E. R. Squibb & Sons, Inc. Pyridine anchors for HMG-CoA reductase inhibitors
US5753675A (en) 1989-03-03 1998-05-19 Novartis Pharmaceuticals Corporation Quinoline analogs of mevalonolactone and derivatives thereof
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5177080A (en) 1990-12-14 1993-01-05 Bayer Aktiengesellschaft Substituted pyridyl-dihydroxy-heptenoic acid and its salts
JP2648897B2 (ja) 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
US5595872A (en) 1992-03-06 1997-01-21 Bristol-Myers Squibb Company Nucleic acids encoding microsomal trigyceride transfer protein
US5470845A (en) 1992-10-28 1995-11-28 Bristol-Myers Squibb Company Methods of using α-phosphonosulfonate squalene synthetase inhibitors including the treatment of atherosclerosis and hypercholesterolemia
US5594016A (en) 1992-12-28 1997-01-14 Mitsubishi Chemical Corporation Naphthalene derivatives
ES2133158T3 (es) 1993-01-19 1999-09-01 Warner Lambert Co Formulacion ci-981 oral, estable y proceso de preparacion del mismo.
US5340583A (en) 1993-05-06 1994-08-23 Allergan, Inc. Antimicrobial lenses and lens care systems
US5739135A (en) 1993-09-03 1998-04-14 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
US5776983A (en) 1993-12-21 1998-07-07 Bristol-Myers Squibb Company Catecholamine surrogates useful as β3 agonists
US5488064A (en) 1994-05-02 1996-01-30 Bristol-Myers Squibb Company Benzo 1,3 dioxole derivatives
US5385929A (en) 1994-05-04 1995-01-31 Warner-Lambert Company [(Hydroxyphenylamino) carbonyl] pyrroles
US5612359A (en) 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
US5491134A (en) 1994-09-16 1996-02-13 Bristol-Myers Squibb Company Sulfonic, phosphonic or phosphiniic acid β3 agonist derivatives
US5541204A (en) 1994-12-02 1996-07-30 Bristol-Myers Squibb Company Aryloxypropanolamine β 3 adrenergic agonists
US5620997A (en) 1995-05-31 1997-04-15 Warner-Lambert Company Isothiazolones
WO1997012613A1 (en) 1995-10-05 1997-04-10 Warner-Lambert Company Method for treating and preventing inflammation and atherosclerosis
ATE344279T1 (de) 1995-12-13 2006-11-15 Univ California Kristalle der mit einem ligand komplexierten ligandenbindedomäne des schilddrüsenhormonrezeptors
US5770615A (en) 1996-04-04 1998-06-23 Bristol-Myers Squibb Company Catecholamine surrogates useful as β3 agonists
US5962440A (en) 1996-05-09 1999-10-05 Bristol-Myers Squibb Company Cyclic phosphonate ester inhibitors of microsomal triglyceride transfer protein and method
US5885983A (en) 1996-05-10 1999-03-23 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
US5827875A (en) 1996-05-10 1998-10-27 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
US5760246A (en) 1996-12-17 1998-06-02 Biller; Scott A. Conformationally restricted aromatic inhibitors of microsomal triglyceride transfer protein and method
TW536540B (en) 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
GB9713739D0 (en) 1997-06-27 1997-09-03 Karobio Ab Thyroid receptor ligands
WO1999038501A2 (en) 1998-02-02 1999-08-05 Trustees Of Tufts College Method of regulating glucose metabolism, and reagents related thereto
JP2002506075A (ja) 1998-03-09 2002-02-26 フォンダテッヒ・ベネルクス・ナムローゼ・フェンノートシャップ セリンペプチダーゼ調節剤
GB9807354D0 (en) * 1998-04-07 1998-06-03 Glaxo Group Ltd Antiviral compound
DE19823831A1 (de) 1998-05-28 1999-12-02 Probiodrug Ges Fuer Arzneim Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen
DE19828114A1 (de) 1998-06-24 2000-01-27 Probiodrug Ges Fuer Arzneim Produgs instabiler Inhibitoren der Dipeptidyl Peptidase IV
DE19828113A1 (de) 1998-06-24 2000-01-05 Probiodrug Ges Fuer Arzneim Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV
DE69940063D1 (de) 1998-07-06 2009-01-22 Bristol Myers Squibb Co Biphenylsulfonamide als zweifach aktive rezeptor antagonisten von angiotensin und endothelin
US6069238A (en) 1998-09-30 2000-05-30 Eli Lilly And Company Spirocyclic C-glycosides
GB9828442D0 (en) 1998-12-24 1999-02-17 Karobio Ab Novel thyroid receptor ligands and method II
US6414002B1 (en) 1999-09-22 2002-07-02 Bristol-Myers Squibb Company Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
TW200514783A (en) 1999-09-22 2005-05-01 Bristol Myers Squibb Co Substituted acid derivatives useful as antiodiabetic and antiobesity agents and method
PH12000002657B1 (en) 1999-10-12 2006-02-21 Bristol Myers Squibb Co C-aryl glucoside SGLT2 inhibitors
US6515117B2 (en) * 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
US6395767B2 (en) 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
US6683056B2 (en) 2000-03-30 2004-01-27 Bristol-Myers Squibb Company O-aryl glucoside SGLT2 inhibitors and method
KR20020014570A (ko) * 2000-08-18 2002-02-25 김충섭 고체분산화시킨 무정형 이프리플라본의 제조방법
US6936590B2 (en) 2001-03-13 2005-08-30 Bristol Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
ES2258141T3 (es) * 2001-04-11 2006-08-16 Bristol-Myers Squibb Company Complejos de aminoacidos de glucosidos c-arilo para el tratamiento de la diabetes y procedimiento.
DK1390377T3 (da) * 2001-05-22 2006-06-19 Pfizer Prod Inc Ny krystalform af azithromycin
CN1630709A (zh) 2001-10-18 2005-06-22 百时美施贵宝公司 人胰高血糖素样多肽－1模拟物和它们在治疗糖尿病和相关状况中的应用
WO2004060347A2 (en) † 2002-09-03 2004-07-22 Transform Pharmaceuticals, Inc. Pharmaceutical propylene glycol solvate compositions
WO2004061433A1 (en) * 2002-12-30 2004-07-22 Transform Pharmaceuticals, Inc. Pharmaceutical compositions with improved dissolution
US7790905B2 (en) * 2002-02-15 2010-09-07 Mcneil-Ppc, Inc. Pharmaceutical propylene glycol solvate compositions
EP1511490A4 (en) * 2002-05-31 2009-03-11 Transform Pharmaceuticals Inc NOVEL CONAZOLE CRYSTALLINE FORMS AND RELATED METHODS, PHARMACEUTICAL COMPOSITIONS AND METHODS
KR20050090437A (ko) 2003-01-03 2005-09-13 브리스톨-마이어스 스큅 컴퍼니 Ｃ-아릴 글루코시드 ｓｇｌｔ２ 억제제의 제조 방법
WO2004076470A2 (en) 2003-02-27 2004-09-10 Bristol-Myers Squibb Company A non-cryogenic process for forming glycosides
BRPI0408140B8 (pt) * 2003-03-14 2018-12-11 Astellas Pharma Inc derivado de c-glicosídeo ou seu sal, composição farmacêutica e uso do derivado de c-glicosídeo ou seu sal
EP1595880A1 (en) * 2004-05-13 2005-11-16 Speedel Pharma AG Crystalline forms of a pyridinyl-sulfonamide and their use as endothelin receptor antagonists
PT1761528E (pt) * 2004-06-11 2008-04-15 Japan Tobacco Inc Derivados de 5-amino-2,4,7-trioxo-3,4,7,8-tetra-hidro-2hpirido[ 2,3-d]pirimidina e compostos relacionados para o tratamento do cancro
AR051446A1 (es) * 2004-09-23 2007-01-17 Bristol Myers Squibb Co Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2)
US7919598B2 (en) * 2006-06-28 2011-04-05 Bristol-Myers Squibb Company Crystal structures of SGLT2 inhibitors and processes for preparing same
CN104829572B (zh) 2014-02-10 2019-01-04 江苏豪森药业集团有限公司 达格列净新晶型及其制备方法

Also Published As

Publication number Publication date
NZ589195A (en) 2011-09-30
ES2521665T5 (es) 2022-02-01
EA028259B1 (ru) 2017-10-31
PH12012500168B1 (en) 2015-11-09
PH12012500168A1 (en) 2015-11-09
SG10201402181SA (en) 2014-07-30
EA201490902A1 (ru) 2015-02-27
RS53638B1 (en) 2015-04-30
IL195882A (en) 2016-06-30
NO20085169L (no) 2009-01-20
JP2016172758A (ja) 2016-09-29
US20080004336A1 (en) 2008-01-03
IL195882A0 (en) 2009-09-01
DK2069374T3 (da) 2014-11-03
NZ589202A (en) 2011-09-30
NO346828B1 (no) 2023-01-23
CA2653344C (en) 2016-06-07
CA2985797A1 (en) 2008-01-03
IL214181A0 (en) 2011-08-31
EA200900066A1 (ru) 2009-06-30
EP2457918A3 (en) 2012-08-29
NZ574346A (en) 2010-12-24
EP3363807B1 (en) 2019-11-13
IL214181A (en) 2017-06-29
TWI421245B (zh) 2014-01-01
CA2924318A1 (en) 2008-01-03
CO6160299A2 (es) 2010-05-20
CN101479287A (zh) 2009-07-08
JP2009545525A (ja) 2009-12-24
JP2015071636A (ja) 2015-04-16
MY148566A (en) 2013-04-30
BRPI0713544B8 (pt) 2021-05-25
CL2007001915A1 (es) 2008-01-18
UA96765C2 (ru) 2011-12-12
ZA200810475B (en) 2010-02-24
CN103145773B (zh) 2015-07-22
ES2521665T3 (es) 2014-11-13
MY173930A (en) 2020-02-27
NO20221233A1 (no) 2009-01-20
KR20090023643A (ko) 2009-03-05
JP5937187B2 (ja) 2016-06-22
EP2069374A1 (en) 2009-06-17
ES2769130T3 (es) 2020-06-24
SI2069374T1 (sl) 2014-11-28
EA018229B1 (ru) 2013-06-28
AU2007265246B2 (en) 2013-02-07
TW201509927A (zh) 2015-03-16
PE20080349A1 (es) 2008-04-25
TW201546054A (zh) 2015-12-16
EA035999B1 (ru) 2020-09-10
US7919598B2 (en) 2011-04-05
JP2019059779A (ja) 2019-04-18
BR122017021516B8 (pt) 2021-07-27
IL214182A (en) 2017-06-29
JP5313889B2 (ja) 2013-10-09
US20110172176A1 (en) 2011-07-14
KR101493102B1 (ko) 2015-02-16
RS53638B2 (sr) 2021-10-29
BRPI0713544A2 (pt) 2013-01-08
NZ589190A (en) 2011-09-30
MX2008015377A (es) 2008-12-16
IL214180A (en) 2017-09-28
IL214182A0 (en) 2011-08-31
ES2659862T3 (es) 2018-03-19
MX339143B (es) 2016-05-13
DK2069374T4 (da) 2021-10-18
SI2069374T2 (sl) 2021-11-30
JP5666651B2 (ja) 2015-02-12
PL2069374T5 (pl) 2021-11-08
EP2069374B1 (en) 2014-07-30
EP3045466A1 (en) 2016-07-20
HRP20141007T4 (hr) 2021-11-12
US8501698B2 (en) 2013-08-06
MX367155B (es) 2019-08-07
BR122017015106B8 (pt) 2021-07-27
CA2924318C (en) 2019-12-24
HRP20141007T1 (en) 2014-12-05
US20130303467A1 (en) 2013-11-14
AR061730A1 (es) 2008-09-17
EA020428B1 (ru) 2014-11-28
EP3045466B1 (en) 2017-12-06
BRPI0713544B1 (pt) 2018-04-17
IL214180A0 (en) 2011-08-31
EA201791254A1 (ru) 2018-03-30
CN103145773A (zh) 2013-06-12
CY1115738T1 (el) 2017-01-25
SG172741A1 (en) 2011-07-28
TWI466876B (zh) 2015-01-01
NO347770B1 (no) 2024-03-18
AU2007265246A1 (en) 2008-01-03
EP2457918A2 (en) 2012-05-30
IL245688A0 (en) 2016-06-30
JP2013209394A (ja) 2013-10-10
WO2008002824A1 (en) 2008-01-03
PT2069374E (pt) 2014-10-30
PE20120776A1 (es) 2012-06-27
JP2017222681A (ja) 2017-12-21
TW201406743A (zh) 2014-02-16
CN101479287B (zh) 2013-03-27
US9453039B2 (en) 2016-09-27
PL2069374T3 (pl) 2015-01-30
CA2653344A1 (en) 2008-01-03
TW200811127A (en) 2008-03-01
TWI519528B (zh) 2016-02-01
BR122017021516B1 (pt) 2021-03-16
BR122017015106B1 (pt) 2019-10-15
HK1127359A1 (en) 2009-09-25
EP3363807A1 (en) 2018-08-22
EP2069374B2 (en) 2021-07-28

Similar Documents

Publication Publication Date Title
EA201171333A1 (ru) Кристаллические сольваты и комплексы производных (1s)-1,5-ангидро-1-с-(3-((фенил)метил)фенил)-d-глюцитола с аминокислотами в качестве ингибиторов sglt2 для лечения диабета
EA200970156A1 (ru) Пиридизиноновые производные
EA200901133A1 (ru) Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение
EA200870127A1 (ru) Полициклические производные аминокислот и способы их применения
MA32175B1 (fr) Oxadiazoanthracènes pour le traitement du diabète
EA200700601A1 (ru) Производные фениламинопиримидина как ингибиторы bcr-abl
NO20056192L (no) Kapaseinhibitorer og anvendelse derav
EA200901138A1 (ru) Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение
EA201001682A1 (ru) Производные фенил- и бензодиоксинилзамещенных индазолов
EA201100482A1 (ru) Кристаллические формы 2-тиазолил-4-хинолинилоксипроизводного, активного ингибитора hcv
EA200802050A1 (ru) Новые гетероарилзамещенные ариламинопиридиновые производные в качестве мек ингибиторов
EA200870475A1 (ru) Ингибиторы 11-бета-гидроксистероид-дегидрогеназы типа 1
NO20084652L (no) Deazapuriner anvendelige som inhibitorer av januskinaser
EA201100007A1 (ru) Производные хиноксалиндиона
EA200870472A1 (ru) Ингибиторы 11-бета-гидроксистероид-дегидрогеназы типа 1
EA201101084A1 (ru) Феноксиуксусные кислоты в качестве активаторов ppar дельта
NO20070224L (no) 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav
ATE442349T1 (de) Diacylglycerol-acyltransferase-hemmer
EA200801996A1 (ru) 2-замещенные производные 4-бензилфталазинонов в качестве гистаминовых h1- и h3-антагонистов
EA201071019A1 (ru) Кристаллические формы производных фениламинопиримидина
NO20082496L (no) Pyrazinderivater
NO20090979L (no) (3-amino-1,2,3,4-tetrahydro-9H-karbazol-9-yl)-eddiksyrederivater
PE20091425A1 (es) Derivados de aminotiazol
NO20091626L (no) MGLUR5-modulatorer
EA200870302A1 (ru) 1,3-диоксанкарбоновые кислоты

Legal Events

Date Code Title Description
PC1A Registration of transfer to a eurasian application by force of assignment
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KG MD TJ TM